PMI R&D, Philip Morris International Research Laboratories Pte. Ltd, Science Park II, Singapore, 117406, Singapore.
PMI R&D, Philip Morris Products S.A, Quai Jeanrenaud 5, 2000, Neuchâtel, Switzerland.
Arch Toxicol. 2021 May;95(5):1805-1829. doi: 10.1007/s00204-021-03020-4. Epub 2021 May 7.
Cigarette smoking is the major cause of chronic obstructive pulmonary disease. Considerable attention has been paid to the reduced harm potential of nicotine-containing inhalable products such as electronic cigarettes (e-cigarettes). We investigated the effects of mainstream cigarette smoke (CS) and e-vapor aerosols (containing nicotine and flavor) generated by a capillary aerosol generator on emphysematous changes, lung function, and molecular alterations in the respiratory system of female Apoe mice. Mice were exposed daily (3 h/day, 5 days/week) for 6 months to aerosols from three different e-vapor formulations-(1) carrier (propylene glycol and vegetable glycerol), (2) base (carrier and nicotine), or (3) test (base and flavor)-or to CS from 3R4F reference cigarettes. The CS and base/test aerosol concentrations were matched at 35 µg nicotine/L. CS exposure, but not e-vapor exposure, led to impairment of lung function (pressure-volume loop area, A and K parameters, quasi-static elastance and compliance) and caused marked lung inflammation and emphysematous changes, which were confirmed histopathologically and morphometrically. CS exposure caused lung transcriptome (activation of oxidative stress and inflammatory responses), lipidome, and proteome dysregulation and changes in DNA methylation; in contrast, these effects were substantially reduced in response to the e-vapor aerosol exposure. Compared with sham, aerosol exposure (carrier, base, and test) caused a slight impact on lung inflammation and epithelia irritation. Our results demonstrated that, in comparison with CS, e-vapor aerosols induced substantially lower biological and pathological changes in the respiratory tract associated with chronic inflammation and emphysema.
吸烟是慢性阻塞性肺疾病的主要原因。人们对尼古丁吸入性产品(如烟电子烟)的潜在危害降低给予了相当大的关注。我们研究了主流香烟烟雾(CS)和毛细管气溶胶发生器产生的电子雾化气溶胶(含尼古丁和香精)对载脂蛋白 E 基因敲除(Apoe)小鼠肺气肿变化、肺功能和呼吸系统分子改变的影响。雌性 Apoe 小鼠每天暴露于来自三种不同电子雾化制剂的气溶胶中 3 小时(每天 5 天/周),持续 6 个月:(1)载剂(丙二醇和蔬菜甘油),(2)基础配方(载剂和尼古丁),或(3)测试配方(基础配方和香精),或暴露于 3R4F 参考香烟的 CS 中。CS 和基础/测试气溶胶的浓度在 35μg 尼古丁/L 时匹配。CS 暴露而不是电子雾化暴露导致肺功能受损(压力-容积环面积、A 和 K 参数、准静态弹性和顺应性),并导致明显的肺部炎症和肺气肿改变,这些改变通过组织病理学和形态计量学得到证实。CS 暴露导致肺转录组(氧化应激和炎症反应的激活)、脂质组和蛋白质组失调以及 DNA 甲基化改变;相比之下,电子雾化气溶胶暴露大大降低了这些影响。与假处理相比,气溶胶暴露(载剂、基础和测试)仅引起肺部炎症和上皮刺激的轻微影响。我们的研究结果表明,与 CS 相比,电子雾化气溶胶在与慢性炎症和肺气肿相关的呼吸道中引起的生物学和病理学变化要低得多。